Patients with upper tract urothelial carcinoma (UTUC) and urinary tract stone history are a high-risk subgroup requiring greater surveillance.

Disitamab vedotin plus toripalimab improved progression-free survival and overall survival when compared to chemotherapy.

Conducting Clinical Research in Low Research Resource Countries: Lessons Learned From the International Registry of Men With Advanced Prostate Cancer Study in Nigeria A retrospective study was ...

A cohort study has found that patients with upper tract urothelial carcinoma (UTUC) who had a history of urinary tract stones ...

Patients with urinary stones show poorer survival in upper tract urothelial carcinoma. Find out how stone history may affect ...

ESMO 2025 bladder cancer highlights include results from KEYNOTE-905/EV-303, RC48-C016, and IMvigor011 studies.

Urothelium is the term for the mucous membrane that lines the urinary tract. This includes the renal pelvis, ureter, urinary bladder and the upper part of the urethra. In the vast majority of cases, ...

For patients with previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC), the combination of enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) (EV+P) continued to ...

The study not only enhances survival prediction but also provides novel evidence for a causal genetic link between prostate cancer and urothelial carcinoma. The team analyzed records of 6,363 prostate ...

Validation of Clinical Dynamic Contrast-Enhanced Magnetic Resonance Imaging Perfusion Modeling and Neoadjuvant Chemotherapy Response Prediction in Breast Cancer Using 18FDG and 64Cu-DOTA-Trastuzumab ...